CDTX Cidara Therapeutics Inc
Price (delayed)
$16.43
Market cap
$179.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$26.75
Enterprise value
-$12.64M
Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its
Highlights
CDTX's equity is up by 41% since the previous quarter
Cidara Therapeutics's quick ratio has increased by 37% from the previous quarter
The company's revenue has shrunk by 95% YoY and by 89% QoQ
The gross profit has plunged by 95% YoY and by 87% from the previous quarter
Key stats
What are the main financial stats of CDTX
Market
Valuations
Earnings
Shares outstanding
10.95M
Market cap
$179.97M
Enterprise value
-$12.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
81.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.91
Revenue
$1.28M
Gross profit
$1.28M
Operating income
-$176.1M
Net income
-$169.83M
EBIT
-$169.83M
EBITDA
-$168.55M
Free cash flow
-$176.66M
Per share
Balance sheet
Liquidity
EPS
-$26.75
EPS diluted
-$26.75
Free cash flow per share
-$27.82
Book value per share
$23.18
Revenue per share
$0.2
TBVPS
$33.83
Total assets
$214.8M
Total liabilities
$51.49M
Debt
$3.58M
Equity
$163.31M
Working capital
$161.18M
Debt to equity
0.02
Current ratio
4.25
Quick ratio
3.99
Net debt/EBITDA
1.14
Margins
Efficiency
Dividend
EBITDA margin
-13,219.3%
Gross margin
100%
Net margin
-13,319.8%
Operating margin
-13,811.9%
Return on assets
-112.6%
Return on equity
-173.3%
Return on invested capital
N/A
Return on capital employed
-102.8%
Return on sales
-13,319.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDTX stock price
How has the Cidara Therapeutics stock price performed over time
Intraday
-7.8%
1 week
-26.62%
1 month
-29.06%
1 year
-23.94%
YTD
-38.88%
QTD
-23.72%
Financial performance
How have Cidara Therapeutics's revenue and profit performed over time
Revenue
$1.28M
Gross profit
$1.28M
Operating income
-$176.1M
Net income
-$169.83M
Gross margin
100%
Net margin
-13,319.8%
The company's revenue has shrunk by 95% YoY and by 89% QoQ
The gross profit has plunged by 95% YoY and by 87% from the previous quarter
CDTX's net income is down by 41% QoQ
Cidara Therapeutics's operating income has decreased by 33% QoQ
Growth
What is Cidara Therapeutics's growth rate over time
Valuation
What is Cidara Therapeutics stock price valuation
P/E
N/A
P/B
0.71
P/S
81.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.91
The EPS has declined by 15% since the previous quarter
CDTX's equity is up by 41% since the previous quarter
CDTX's price to sales (P/S) is 126% higher than its last 4 quarters average of 36.2
The company's revenue has shrunk by 95% YoY and by 89% QoQ
Efficiency
How efficient is Cidara Therapeutics business performance
Cidara Therapeutics's return on equity has increased by 21% QoQ and by 21% YoY
Cidara Therapeutics's return on assets has decreased by 6% QoQ
Dividends
What is CDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDTX.
Financial health
How did Cidara Therapeutics financials performed over time
Cidara Therapeutics's quick ratio has increased by 37% from the previous quarter
The total assets has grown by 32% from the previous quarter
CDTX's debt is 98% lower than its equity
Cidara Therapeutics's debt to equity has soared by 103% YoY but it has decreased by 33% from the previous quarter
CDTX's equity is up by 41% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.